BI 99179

BI 99179 is a selective small molecule inhibitor suitable for the in vivo validation of type 1 fatty acid synthase (FAS) as a therapeutic target for lipid metabolism-related disorders (lipid metabolism disorder) which has been discovered…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BI 99179 is a selective small molecule inhibitor suitable for the in vivo validation of type 1 fatty acid synthase (FAS) as a therapeutic target for lipid metabolism-related disorders (lipid metabolism disorder) which has been discovered by Boehringer Ingelheim.

Further reading

Alexandra D'Arcangelis, John Bajor, Kimberly Campbell, Helen Knaggs. U.S. Patent 53631, 2005.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329234632 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.